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ABSTRACT
EARLY ONSET MARIJUANA USE AND ADULT MENTAL HEALTH
By
Christine Murphy Andrews
April 11, 2016

INTRODUCTION: The impact of marijuana use has become a national topic with the increase in state’s
legalizing or decriminalizing the use of the drug. To understand the impact this new trend may have on the
population, it is necessary to characterize the interaction between marijuana use and health outcomes.
Previous research has focused on the acute effects of marijuana on mental health and longitudinal impacts of
marijuana use in the adolescent population. However there are no previously published studies on the
impact of early onset marijuana use on adult mental health.
AIM: This study aims to determine the prevalence of early onset marijuana use and if there is a statically
significant association between early onset marijuana use (<14 years old) and increased prevalence of
adverse mental health outcomes in adult life.
METHODS: This study was conducted using data from the 2014 National Survey on Drug Use and Health. The
study population included 41, 285 participants 18 or older at the time of the cross-sectional survey. Adult
mental health outcomes were modeled for both early onset marijuana users and non-early onset marijuana
users using a multiple logistic regression model to calculate both adjusted and unadjusted odds ratios (AOR’s,
OR’s) with 95% confidence intervals. Statistical analysis was performed to examine the association between
early onset marijuana use and negative adult mental health outcomes including serious mental illness, any
mental illness and lifetime depressive episodes.
RESULTS: This study found that in adults aged 18 and older the prevalence of early onset marijuana use was
8.3%. The prevalence of early onset marijuana use varies by gender, with a prevalence of 5.1(95% CI 4.7-5.2)
for males and 3.3(95% CI 3.1-3.5) for females. Early onset marijuana use had a statistically significant
association with all three indicators of poor adult mental health. The AOR for early onset marijuana use and
serious mental illness was 2.3(95% CI 1.972-2.758). The association between early onset marijuana use and
adult depressive episode had an AOR of 2.1(95% CI1.906-2.389).
DISCUSSION: These findings suggest that early onset marijuana use is a risk factor for adverse mental health
outcomes in adulthood. Consistent with findings from other nationally representative surveys, the prevalence
of early onset marijuana use is higher in males than females. Early onset marijuana use is associated with
increased odds of past year serious mental illness and past year any mental illness. This suggests that
legislature considering marijuana legalization must also consider policies addressing under age use of the
drug. Further longitudinal research is needed to father assess the association between early onset marijuana
use and adult mental health.
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1. Introduction
1.1 Background
The impact of the use of marijuana or cannabis has become a topic of popular debate as
states begin to shift towards legislature legalizing or decriminalizing the sale of the drug. While
marijuana has existed in the United States since the American Revolution as a byproduct of the
hemp trade, it was not until the early 20th century that Mexican immigrants introduced the use
of marijuana as a recreational drug1,2. Similar to opiates and cocaine, marijuana was available
both from pharmacies and over the counter. Alongside the cultural shift of Prohibition, states
began outlawing marijuana and by 1925, 26 states had passed laws prohibiting its sale3.
Marijuana became a Schedule I drug with the passing of the federal Controlled Substances Act
in 19703. Schedule I drugs meet the following criteria: high potential for abuse and no current
justification for medical use4 Possession and sales of Schedule I drugs is classified as a federal
felony.
Over the last decade, multiple states have begun introducing legislation to either allow
the direct sale of marijuana, decriminalize possession of the drug or allow the drug to be used
for medicinal purposes2. Unlike pharmaceuticals, relatively few clinical trials have been
conducted on the medicinal use of marijuana leading to a lack of knowledge in the potential
health benefits or harm as well as correct dosing and potency levels3. Past research on
marijuana has focused on the impacts of its recreational use and prevalence primarily from a
cross-sectional view. Within the job setting, marijuana use has been linked to higher rates of
absenteeism and occupational injuries5. In adolescents, marijuana has been associated with a
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higher likelihood of dropping out of school, decreased academic performance and a drop in IQ
over time6,7. While numerous associations between marijuana use and poor health outcomes
have been established, there is a lack of data on the effects of early marijuana use on adult
mental illness8. Additionally, while many studies have linked marijuana use to an increase in
psychosis, few have examined the impact of marijuana on less acute mental illness in the adult
population9. This study will focus on determining if there is an association between early onset
marijuana use and mental health outcomes in adult life, using data from the SAMHSA NSDUH
2014 public-access file.

1.2 Research Questions
1. What is the prevalence of early onset marijuana use in the United States population?
2. Does the prevalence of early onset marijuana use vary between men and women?
3. Is there an association between early onset marijuana use (<14 years old) and adverse
mental health outcomes in adult life?

1.3 Research Aims
This study aims to determine the prevalence of early onset marijuana use and if there is
a statically significant association between early onset marijuana use (<14 years old) and
increased prevalence of adverse mental health outcomes in adult life.
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1.4 Research Hypotheses
Ha: Adults who reported first onset of marijuana use before the age of 14 years old will
have an increase in adverse mental health outcomes in their adult life.

Ho: Adults who reported first onset of marijuana use before the age of 14 years old will
not have an increase in adverse mental health outcomes in their adult life.
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2. Review of the Literature
2.1 Marijuana
Marijuana or cannabis is an illicit drug derived from the dried flowers, stems and leaves
of the Cannabis sativa, or the hemp plant4. Marijuana is most commonly found as a shredded
dry mixture resembling tobacco, but can also be in an oil or resin form4. The drug is typically
smoked, ingested in a food, or used as a tea. The use hand-rolled cigarettes (joints), pipes and
water pipes (bongs) are the most common ways to smoke marijuana3. The effects of marijuana
depend on many different factors including the dose used, the method of use, the setting of
use, the user’s previous experiences with cannabis and the expectations of the user 10. The
effects of cannabis range from euphoria, relaxation, and perception changes including the
intensification of sense such as smell and taste11. The majority of marijuana users report that
they use in order to achieve this “high” and the increased sociability it provides when used in a
group context. The marijuana ‘high” has an onset about 30 minutes after a cannabis dose is
taken and lasts for about 1 to 2 hours3.
Marijuana’s active agent is the chemical delta-9- tetrahydrocannabino, known as THC3.
THC is a psychoactive chemical affecting the mind and the body through ingestion or inhalation.
THC impacts the cannabinoid receptors in the brain when it attaches to them after initiation
through the bloodstream. The activity of nerve cells is impacted by THC including receptors for
memory, pleasure, thought, coordination, concentration and temporal ability. This leads to
short terms effects such as memory-loss, disabled perception, difficulty in concentration and
learning and loss of coordination3. Long-term marijuana use can lead to physical dependence
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and withdrawal symptoms after discontinuation. Recent studies have shown that marijuana is
more addictive than previously believed, with 1 in 11 or 9% of cannabis users becoming
dependent at some point in their lifetime12,13.
Marijuana use has also been linked to physical symptoms and disease. Similar to
smoking, marijuana use leads to an increased risk of cancers of the head, neck, lungs and
respiratory tract due to the carcinogens and toxins inhaled during use1. Other respiratory
health problems marijuana smokers are at risk for include asthma, emphysema and COPD 14.
Marijuana use during pregnancy has been associated with delays in fetal development and low
birth weight. Preliminary research also suggests that marijuana use during pregnancy can
contribute to the risk of rare forms of cancer in the child including neuroblastoma15.
Additionally research has shown an association between prenatal marijuana use and
malformation in the neurological pathways moderating the emotional functioning of the
fetus16.

Impact on the Brain
A large amount of animal research has focused on the direct impact that marijuana has
on the brain and neurological system through the dopamine pathways. Dopamine, a
neurotransmitter in the brain, impacts movement, motivation, reward and addiction. Most
addictive drug use increases dopamine in the brain, flooding the dopamine pathways and
engaging the pleasure seniors and positive feedback loop17. Studies on the impact of marijuana
on the release of dopamine in the human brain are mixed. Two recent studies reported an
increase in dopamine in the human brain after cannabis use18,19. Conversly, a recent study on
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the impact of recreational doses of marijuana concluded that recreational cannabis use does
not release significant amounts of dopamine into the brain20. A systematic review examined
and evaluated studies on the impact marijuana has on dopaminergic signaling in the human
brain. While some studies showed hat the active agent of marijuana, THC, has been associated
with increased levels of dopamine in the brain, other studies concluded there is no impact from
marijuana use on dopamine pathways 21. The review concluded that more research is needed
into the actual effects marijuana has on the human brain because of conflicting study reports
and a lack of standardization in the research methods used across the studies reviewed. Recent
studies cited in the systematic review suggested that while there is little evidence to support
that acute marijuana use impacts the dopamine receptors in the human brain, chronic
marijuana use reduces both dopamine synthesis and dopamine release capacity22.

Marijuana Prevalence
Marijuana has grown to become the most popular and widely spread illicit drug in the
United States. Results from the 2013 National Survey on Drug Use and Health (NSDUH) find that
19.8 million or 7.5% of persons aged 12 or older were current users of marijuana, an increase
from a rate of 5.8% in 200223. Marijuana was the most reported illicit drug of current use for all
age categories, with young adults having the highest prevalence rates of current marijuana use
at 19.1% (Abuse, n.d.). The rate of current use of marijuana was higher in males(7.9%) than
females(6.2%). The daily use of marijuana has rapidly increased in the U.S. with 5.7 million
persons aged 12 or older reporting daily use in 2013 compared to 3.1 million reporting daily use
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in 2006. The amount of daily or almost daily users in the U.S. represented 41.1% of marijuana
users.
Marijuana dependence continues to contribute to the burden of disease in the United
States. In 2013, 4.2 million persons reported marijuana dependence or abuse. The rate of
marijuana dependence or abuse has remained similar from 2002(1.8%) to 2013(1.6%).
Marijuana related medical emergencies have increased 21% from 2009 to 2011, with 456,000
marijuana related medical emergencies reported in 20112. Currently, little research has been
done on the cause of the increase-it is unknown whether it is due to increased marijuana
potency, increased use of marijuana or other factors. Some studies have found a recent
increase in the potency of THC content in marijuana being sold in the United States, suggesting
that new users may experience a high risk for adverse effects during use 24.

2.2 Mental Health
Mental health and its impact on the global burden of disease is a relatively new focus of
public health interest. Historically, mental health disorders have not been a health priority,
both globally and nationally, with little funding being allotted for the study and treatment of
behavioral health disease. Prevalence and incidence rates for mental health disorders have
been difficult to obtain due in part to a lack of reporting and little to no mental health resources
available to diagnose and treat psychiatric diseases25. Typically healthcare services for mental
health disorders have been segregated from the larger pool of healthcare resources, falling
behind both communicable and chronic disease.
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Research in the last 15 years has begun to gain a better perspective on the prevalence
of mental health disorders at the population level. In the most recent prevalence study (when)
conducted by the National Institute of Mental Health (NIMH), the prevalence of any mental
illness(AMI) among U.S. Adults is 18.1%26. The NIMH defines “Any Mental Illness” as a mental,
behavioral or emotional disorder that meets DSM-IV criteria and has been diagnosed within the
past year26. The NIMH reports that serious mental illness (SMI), or mental illness that results in
serious functional impairment has a prevalence of 4.2% representing about 9.8 million adults in
the U.S27.
With the shift in focus from the burden of disease mortality to the burden of disease
morbidity, mental health disorders have begun to receive attention. The burden of mental
health disorders far outweighs its allocated recourses, both internationally and within the
United States. The true costs of mental health disorders are hard to determine due to various
under identified key components28. Economically, mental health disorders create a cost burden
in indirect costs such as loss of productivity, loss of income, and cost of social support in
addition to upfront costs for diagnosis and treatment. Similar to rising healthcare costs due to
chronic disease, the burden of mental health disorders falls on the population as a whole.
There are multiple reports on the monetary costs of mental health illness both globally
and within the U.S. The Agency for Healthcare Research and Quality (AHRQ) reported mental
disorders as one of the top five most costly conditions in terms of direct medical spending,
rising in costs from $35.2 billion to $57.5 billion over a 10 year period29. It is estimated that
persons with serious mental illness that an individual reduction of earnings of $16, 306 in a 12
month period, which generalizes to an annual loss of $193.2 billion in the U.S. general
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population per year28. The World Health Organization (WHO) recently estimated the global cost
of mental health disorders to be $2.5 trillion with a projected increase to $6 trillion by 2030 30.

Anxiety
The most frequent mental health disorder addressed in the primary care setting is
generalized anxiety disorder. Generalized anxiety disorder is categorized by anxiety, tension
and psychosomatic symptoms such as sleep disturbances and weight loss that persist for 6
months of longer31. A systematic review of the prevalence and incidence literature for anxiety
disorders internationally concluded that the best estimate for prevalence of 1-year and lifetime
prevalence of all anxiety disorders was 10.6% and 16.6% respectively32, The prevalence of
generalized anxiety disorder was found to be 2.6% for 1-year prevalence and 6.2% for lifetime
prevelence32. The small ratios between 1-year and lifetime prevalence of both all anxiety
disorders and generalized anxiety disorder seems to suggest that the majority of people
experience anxiety disorders on a continuous or reoccurring basis.
The prevalence of anxiety disorders in the United States continues to be the highest of
any mental health disorder in recent surveys. The 2005 National Comorbidity Survey reported a
lifetime prevalence of 28.8% for any anxiety disorder in the United States 33. The age category of
30 to 44 years old reported the highest anxiety lifetime prevalence at 35.1% , while 18 to 29
and 45 to 59 reported a lifetime prevalence of 30.2% and 30.8%, respectively33. Older adults(60
and above) reported much lower rates of anxiety, with a lifetime prevalence of 15.3% 33. A study
of gender differences and anxiety disorders in the United States concluded that the lifetime and
1-year prevalence ratios between males and females were 1:1.7 and 1:1.79, respectively34

9

Few studies have been done recently on the economic costs of anxiety disorders both
globally and in the United States. In the 1990’s the economic costs of anxiety disorders in the
United States were estimated to be 42.3 billion a year, approximately one-third of the S148
billion spent annually on healthcare35. A more recent study on the cost of mental health
disorders in Europe found that anxiety disorders accounted for €74.4 billion of a total of
€798billion spent on brain disorders in 201036.

Depression
Depression is one of the most common mental health disorders in the world and is
characterized by feelings of intense sadness, lack of appetite, loss of sleep and in severe cases
thoughts and actions of suicide37. Currently, the WHO estimates that globally, 300 million
people suffer from depression37. Additionally, the WHO categorizes depression as the third
most important cause of disease burden in their 2004 report on the burden of global illness 38 A
recent study on the occurrence of depression across cultures concluded that while lifetime
prevalence of depression was greater in high income countries than low or middle income
countries, 1-year prevalence of depression had no significant difference39.
A recent study of lifetime prevalence of mental health disorders in the United States
concluded that depression has a lifetime prevalence of 16.6%33. The highest lifetime prevalence
of depression was in the 30 to 44 age range with a prevalence of 19.8%33. The 45 to 59 and the
18 to 29 age ranges reported lifetime prevalence’s of 18.8% and 15.4%, respectively33. Again,
older adults reported the lowest lifetime prevalence of depression at 10.6%33. The National

10

Institute of Mental Health report a 1-year prevalence of adult major depression as 6.6%40. The
prevalence of major depression is higher in females than males at 8.2% and 4.8%, respectively 40
The economic costs attributed to depression by the WHO are the highest out of any
mental disorder. In the US, depression accounts for 3.75% of all DALYs and 8.3% of years lived
with disability (YLDs)41. Recently, the WHO classified depression as the fourth leading cause of
disability globally and projected that by 2020 it will become the second leading cause of
disability42 Several studies have quantified the equivalent monetary loss attributed to days of
work missed due to depression, with ranges from $30.1 billion to $55.5 billion 42. Economic
costs of depression have increased in the US by 21.5% ($173.2 billion to $210.5 billion) between
2005 and 201043

2.3 Mental Health and Marijuana Use
Marijuana use has long been associated with outcomes related to mental health status
in both adults and adolescents including depression, anxiety and psychosis14. Current research
has yielded conflicting results on whether incidence of mental disorders increases with
marijuana use. A recent study of US high-school students found that when controlling for social
economic status (SES), chronic marijuana use was still associated with poor mental health6.
Additionally, the study found that the association became insignificant when controlling for the
use of tobacco and alcohol, suggesting a difficulty in identifying the impact of marijuana versus
that of tobacco and alcohol.
A cohort study of young adults recruited their freshman year of college examined the
association between marijuana use in college and mental health outcomes 10 years post-
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matriculation. The study separated the cohort into groups describing their trajectory of
marijuana use which included Non-Use, Low-Stable, Early-Decline, College-Peak, Late-Increase
and Chronic. The study found that both the Late-Increase and Chronic group of marijuana users
reported significantly lower mental health 10 years post-matriculation than the other groups8.
A cross-sectional interview study of young adults (18-30) examined the association
between the level of marijuana use and mental health disorders. The sample included 1, 072
non-users and 521 users of which 252 were categorized as marijuana dependent and 269 were
not44. The study concluded that both dependent and non-dependent users have higher odds of
having mood disorders compared to the general population (OR 17.75 p<0.001 and 8.91
p<0.001 respectively)44 When adjusted for childhood adversity and other substance use, the
dependent marijuana group have significantly higher odds of having a mental health disorder
than the non-dependent group(OR=2.40 p<0.001)44.

Anxiety
A cohort study of adolescent Australians that followed participants until the age of 29
years concluded that daily use of marijuana contributed to the development of anxiety
disorders in young adults. A cohort of adolescents (mean age 14.9–17.4 year) with a sample size
of 1,943 were followed over a span of 15 years in their late 20’s. Both daily and weekly users in
adolescence had higher OR’s of having an anxiety disorder at 29 years old, OR 2.5 and 3.2
respectively45.
A systematic review of literature on the association between marijuana use and anxiety
disorders examined 16 studies. High frequency marijuana users were found to have a higher
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rate of anxiety disorder, while those with anxiety disorders were also found to have a higher
rate of marijuana use46. The directionality of the association between marijuana and anxiety
was unable to be determined through review of the literature.
A meta-analysis of 31 studies examined the association between marijuana use and
anxiety. The 31 studies drew from 10 countries and 112, 000 noninstitutionalized partisans 47 In
the analysis a positive association was found between marijuana use and anxiety(OR = 1.24,
95% CI: 1.06-1.45, p = .006; N = 15 studies) and marijuana use disorder and anxiety(OR = 1.68,
95% CI: 1.23-2.31, p = .001; N = 13 studies)47. Additionally, the comorbidities of depression and
anxiety were positively associated with cannabis use47. These findings suggest that heavy and
chronic marijuana use that needs treatment is more likely to be associated with anxiety than
non-disordered marijuana use.

Depression
A cross-sectional study of adults using Wave I of the National Epidemiologic Survey on
Alcohol and Related Conditions (NESARC-I) examined the association between marijuana use
and depression stratified by gender. The study divided partisans with depressive disorders
(N=3416) into categories determined by their marijuana use. The categories included no use,
occasional use and regular use of marijuana over the past year. The Quality of Life
questionnaire was used to assess depression. Overall the study found that women who were
regular cannabis users reported a high score on the depression scale, while men had no
significant differences between users and non-users48.
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A longitudinal study of young adult (18-24) women in Rhode Island examined the
change in depression symptoms relative to marijuana use. The partisans (n=332) were
randomly chosen from a clinical trial of a marijuana intervention for sexually active, young adult
females. After controlling for alcohol use, the study found that there was a positive association
between a reduction in marijuana use and a reduction in depression symptoms. Both those
who reported mild(b=−0.26; 95% CI:−0.44,−0.08; P=.004) and moderate/severe depression (b =
−0.50; 95% CI: −0.68,−0.33; P < .001) had significant reductions in symptoms with a reduction in
marijuana use49.
A meta-analysis of longitudinal studies of the association between marijuana use and
developing depression examined data from 14 studies. The total number of subjects included in
the qualitative analysis was 76, 05850. Positive associations with developing depression were
found for both regular and heavy marijuana use. Regular marijuana users had an OR of
1.17(95% CI 1.05-1.30) for developing depression when compared with non-users, while heavy
marijuana users had an OR of 1.82(95% CI 1.21–2.16) when compared with non-users50.

2.4 Early Onset Marijuana Use
Multiple federal national surveys have monitored the use of marijuana in adolescents
since the late 1970’s. The Monitoring the Future survey, collects an annual, representative
sample of public and private secondary school students in the United States. Beginning in 1975,
the survey collected data from 12th graders and in 1991 began to collect data from grades 8, 10
and 12. Administered by the University of Michigan, it is supported with grants by the National
Institute on Drug Abuse. In the most recent marijuana use prevalence data from the Monitoring
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the Future study, lifetime use prevalence for grades 8, 10 and 12 were 15.6%, 33.7% and 44.4%,
respectively, in 201451. Current marijuana use, defined as use in the past 30 days, was 6.5% for
8th grade, 16.6% for 10th grade and 21.2% for 12th grade51. The prevalence of daily use of
marijuana for grades 8, 10 and 12 combined was 3.3% in 2014. When broken down by grade
level, daily marijuana prevalence rates were 1.0%, 3.4% and 5.8%, respectively51. The
Monitoring the Future study does not collect data on age of initiation of marijuana use.
The National Survey on Drug Use and Health (NSDUH), the survey being used for this
thesis, is a nationally representative sample of the noninstutionalized United States population
age 12 and older. More information on the methodology of this annual survey can be found in
the Methods section of this paper. Data from the 2013 NSDUH on early onset marijuana use
reports that the prevalence of current marijuana use (past 30 days) was 7.1% in youth ages 12
to 17. When stratified by gender, past month marijuana use for ages 12 to 17 was higher in
males at 7.9%, compared to females at 6.2% for 2013. When stratified by age, past month
marijuana use prevalence was 1.0% for ages 12 or 13, 5.8% for ages 14 or 15 and 14.2% for ages
16 or 17. The NSDH had no reported data on the daily use of marijuana in the age group 12 to
17 years, although it does ask survey questions about age at first use of marijuana.
The Youth Risk Behavior Surveillance System (YRBSS) also collects annual data on the
use of marijuana in youth in grades 9 to 12. The YRBSS is a cross-sectional survey designed and
administered annually by the Centers for Disease Control and its state partners. While there is a
middle school version of the YRBSS, which surveys students in the age group of interest to this
thesis, the middle school survey is not nationally representative at this time and is only
available at the state-level estimate52. The most recent YRBSS data from the 2013 survey
15

reported a national lifetime prevalence of marijuana use as 40.7%53. For males and females the
lifetime marijuana use prevalence was 42.1% and 39.2% respectively54. 23.4% of high school
students reported currently using marijuana (in the past 30 days), with 25.0% of males
reporting current use compared to 21.9% females53. Early onset marijuana use captured as
having tried marijuana before the age of 13 had a reported prevalence of 8.6%, with 11.1% and
6.2 for males and females respectively54.

2.5 Conclusion
The purpose of this research study is to assess whether early onset marijuana use is
correlated with negative mental health outcomes in adult life. While the prevalence of
marijuana use in youth ages 12 to 17 is widely monitored and reported in the United States,
there are few studies outside of the Youth Risk Behavior Surveillance System that collects data
on the age of initiation of marijuana use. Previous studies have found associations between
marijuana use and poor mental health outcome such as anxiety, depression and psychosis 45–
50,55,56

. This thesis will expand on previous research that examined the association between

marijuana use and mental health by focusing on a subset of marijuana users (early onset users)
and their mental health outcomes in their adult life. An understanding of the relationship
between early onset marijuana use and mental health in adult life can help behavioral health
clinicians identify those who are at a higher risk for poor mental health outcomes and target
individualized interventions to such a population. Focusing on early onset users of marijuana
(<14 years) assess an at risk population that if often missed in survey’s of high school drug use.

16

Additionally, assessing the relationship between early onset marijuana use and adult mental
health can help legislative bodies make important decisions concerning the legalization of
marijuana within the United States.
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3. Methods

3.1 Study Sample and Design
The data for this thesis analysis was provided by the Substance Abuse and Mental
Health Services Administration (SAMHSA). The data set used was the National Survey on Drug
Use and Health (NSDUH), an annual federal survey that is the primary method of data collection
on illicit drug, alcohol and tobacco use in the US civilian, noninstutionalized population aged 12
years or older. The NSDUH also includes several modules of questions pertaining to mental
health. This cross-sectional complex survey has been conducted by SAMHSA since 1971 through
face-to-face or CAI interviews at the participant’s place of residence. The residences included in
the survey are private households, noninstutionalized group quarters (shelters, dormitories)
and military bases. Populations excluded in the survey are the homeless, the institutionalized
(jails, hospitals) and active duty military. The survey includes a $50 incentive for participants
and includes respondents from all 50 states and the District of Columbia. Publically availed data
file for the NSDUH survey from 1979 to 2014 are available on SAMHSA’s website. The specific
data set analyzed was the publically available 2014 NSDUH SAS file.
The NSDUH is sponsored by SAMHSA and the U.S Department of Health and Human
Services. The survey methodology is planned and managed by SAMHSA’s Center for Behavioral
Health Statistics and Quality. Data analysis is contracted out and done by RTI International.
Historically, SAMHSA has presented the NSDUH data in a comprehensive series of reports and
detailed tables. The detailed tables are split into substance abuse and mental health and
present corresponding prevalence statistics on characteristics of interest. The reports issued by
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SAMHSA provide detailed data that focuses on specific topics of interest at the national level.
Past topics have included substance abuse and mental health treatment utilization, illicit drug
use prevalence and suicide. State level estimates for all survey questions are available for all
years the survey was collected.
3.2 Variables of Interest
Variables of interest for this study, along with their presents and a description of what
they capture are also detailed in Table 1 in the appendix.
Demographic Variables
Five demographic variables of interest were included in the sample analysis and are
displayed in Table 1 in the Results section. One of the variables, sex (IRSEX) was a dichotomous
categorical variable and categorized as 1=Male, 2=Female. The remaining four variables were
categorical, two were modified and two were unmodified. The two modified categorical
variables were education level (EDUCCAT2) and age (CATAG7). The original levels of education
were less than high school, high school graduate, some college, college graduate and 12 to 17
year olds. As mentioned previously, data concerning those under the age of 18 was removed
from this data subset. The modified education variable did not contain a level for 12 to 17 years
old. The original age variable levels were 12 to 13 years old, 14 to 15 years old, 16 to 17 years
old, 18 to 20 years old, 21 to 25 years old, 26 to 34 years old and 35 or older. The modified age
variable was categorized to 18 to 20 years old, 21 to 25 years old, 26 to 34 years old and 35 or
older. The remaining categorical variables, race (NEWRACE2) and income (INCOME) maintained
their original levels in the analysis. The variable race(NEWRACE2) contained levels Non-Hispanic
White, Non-Hispanic Black/African-American, Non-Hispanic Native American/Alaskan Native,
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Non-Hispanic Native Hawaiian/Other Pacific Islander, Non-Hispanic Asian, Non-Hispanic more
than one race and Hispanic. The variable income (INCOME) contained the levels Less than $20,
000, $20, 000-$49, 999, $50, 000-$74, 999 and $75, 000 or more.

Independent Variable
The intendant variable used in this analysis was marijuana age of first use (MJAFU). The
initial survey questions asked respondents to report their believed first age of marijuana use.
SAMHSA later recoded the continuous variable into a categorical variable prior to releasing the
public use data set. The variable marijuana age of first use was used unmodified in its
categorized recode for this analysis. The categorical levels were 14 years or younger, 15 to 17
years old, 18 years or older, non-user.

Dependent Variables
The three dependent variables used in this analysis were dichotomous categorical
variables. Two variables, any mental illness (AMIYR_u) and serious mental illness (SMIYR_U)
were unmodified dichotomous categorical variables with levels 0= no and 1=yes. The variable
any mental illness(AMIYR_U) captured any mental illness within the past year while the variable
serious mental illness (MMIYR_U) captured any serious mental illness within the past year. Both
variables are determined by predictive modeling based on participant’s responses to a
functional impairment scale and a psychological distress scale included in the NSDUH survey.
The predictive model produces a variable SMIPP_U, which is then used to determine the
classification of the respondent. If SMIPP_U is greater than or equal to 0.0192519810, then the
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respondent is classified as having past year AMI (AMIYR_U=1). If If SMIPP_U is greater than or
equal to 0.260573529, then the respondent is classified as having past year SMI (SMIYR_U=1).
The variable adult lifetime major depressive episode (AMDELT) was recoded as a
dichotomous categorical variable with levels 0=no, 1=yes for ease of analysis. The original
levels for AMDELT were 1=yes and 2=no. The depression variable captured lifetime incidence of
depression as reported by the participant, based on major depressive episode indicators. In
order to be classified as a “yes”, the participant had to report experiencing at least five out of
the nine criteria used to define an adult as having had MDE in their lifetime, where at least one
of the criteria is a depressed mood or loss of interest or pleasure in daily activities. All
dependent variables were analyzed using the standard analysis weight, ANALWT_C, as
recommended by the survey codebook.

3.3 Statistical Analysis
All statistical analyses for this study were done in SAS 9.4. The study sample from the
2014 NSDUH contained 67, 901 participants and had an 81.94% response rate. For the purpose
of this thesis, analysis was limited to participants 18 and older. This was done in order to
examine the data that pertained to adults in the survey. After application of this limitation to
the data, the sample size used for analysis was 41, 285.Missing values of dependent variables
marijuana age at first use( MJAFU), adult major depressive episode (AMDELT), adult severe
mental illness in past year(SMIYR_U) and adult any mental illness in past year (AMIYR_U) were
deleted due to their small cell size. All variables in the original public use data set that did not
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pertain to the study sample were dropped for ease of SAS analysis. Figure 1 shows the selection
process for the study sample.
The research questions addressed in this analysis were (1) What is the prevalence of
early onset marijuana use in the United States population?, (2) Does the prevalence of early
onset marijuana use vary between men and women?, (3) Is there an association between early
onset marijuana use (<14 years old) and adverse mental health outcomes in adult life?
Descriptive statistics for this study were conducted using PROC SURVEYFRQ and are detailed in
Table 1. Descriptive statistics were conducted for gender, race, age, education level and
income. Rao-Scott chi-square analysis, using the CHISQ option in the SURVEYFREQ procedure,
was used to identify potential associations and confounders among the demographic variables.
PROC SURVEYFREQ, was also used to find the prevalence rates for research questions 1 and 2.
The Rao-Scott chi-square analysis was also used to determine if there was a statistically
significant association between the independent variable marijuana age of onset(MJAFU) and
the selected dependent variables severe mental illness incidence in the past year (SMIYR_U,
any mental illness incidence in the past year(AMIYR_U) and major depressive episode incidence
in the past year(AMDELT).
Multiple logistic regression modeling was then used to examine research question and
to determine the odds ratios of the associations between the independent variable (MJAFU)
and the dependent variables (AMDELT, SMIYR_U, AMIYR_U). PRO SURVEY LOGISTIC was used
to build the logistic regression models. The NSDUH codebook provided the appropriate weight
and strata to include when building the logistic regression model. The weight used was
ANALWT_C and the strata used was VESTR. All analyses were conducted at the α=.05 level of
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significance. Confounders controlled for in the logistic regression modeling and adjusted odds
ratios were age, gender, race, education level and income.
All analysis was done using SAS 9.4. Demographic and descriptive statistics for the study
sample are reported in Table 1. The final study sample size was n=41, 285 after those who were
under the age of 18 at the time or participation were removed from the sample. SAMHSA
provided weights were used to calculate frequencies and percent’s. Regarding gender, 48.2%
of the sample was male and 51.8% of the sample was female. The racial breakdown of the
sample was 65.4% Non-Hispanic White, 11.7% Non-Hispanic Black, 0.5% Native
American/Alaskan Native, 0.4% Native Hawaiian/Other Pacific Islander, 5.3% Asian. 1.5% MultiRacial and 15.3% Hispanic. The majority of participants had a high school degree or higher,
28/9% reported high school graduation while 30.7% reported college graduation. A large
majority of the sample was 35 or older (69.7%) due in part to the limiting of the study sample to
respondents aged 18 or older. With respect to yearly income, 18.1% reported %20, 000 or less,
31% reported $20, 000 to $49, 999, 16.7% reported $50, 000 to $74, 999 and 34.2% reported
$75, 000 or higher.
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4. Results

4.1 Descriptive Statistics of Sample

Descriptive statistics pertaining to the sample characteristics by marijuana age of onset
can be found in Table 2. The final sample size for early onset marijuana users was 4, 321 and
the final sample size of non-early onset marijuana users was 36, 964. The final weighted
percent’s were 91.7% non-early onset marijuana users and 8.3% early onset marijuana users.
Within the study sample (n=41, 285) 4.5 %(95% CI 4.2-4.8) were participants 35 or older who
reported early onset marijuana use. The second largest age group to report early onset
marijuana use was ages 26 to 34 years with 2.0%(95% CI 1.8-2.1) of the study sample. With
respect to gender males with early onset marijuana use made up 5/1%(95% CI 4.7-5.2), while
female early onset marijuana users made up 3.3%(95% CI 3.1-3.5). White participants reported
the highest early onset marijuana use at 5.9%(95% CI 5.6-6.2), while the next largest racial
group to report early onset marijuana use was Hispanics at 1.1%(85% CI 0.99-1.2). Those who
were high school graduates and those with some college reported higher rates of early onset
marijuana use at 2.7%(95% CI 2.5-2.9) and 2.5%(95% CI 2.3-2.7) respectively. Income levels
were split with similar rates of early onset marijuana use being reported in the $20, 000-$49,
999 bracket(2.7% 95% CI 2.5-2.9) and the $75, 000 or greater bracket(2.4% 95% CI 2.2-2.6).

4.2 Bivariate Analysis
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Rao-Scott analysis was done on demographic characteristics and the independent
variable (MJAFU) to determine if there was any statistically significant association between the
two. All demographic variables included (age, gender, race, income and education) were found
to have a statistical significance with the independent variable marijuana age at first use
(MJAFU) (p<0.0001). As a result of their statistical significance with the independent variable,
demographics characteristics were controlled for in later analysis. Table 2 includes the RaoScott chi-square analysis of the demographic variables
Rao-Scott chi-square analysis was also performed on the association between the
independent variable (MJAFU) and the three outcomes of interest, AMDELT, AMIYR_U and
SMYYR_U). Table 3 displays the conclusions of the chi-square testing of deadened variables.
The dependent variable any depressive episode in the last year(AMDELT) was found to have a
statistically significant association with MJAFU (p<0.0001). Both dependent variables addressing
mental illness (any mental illness in last year and severe mental illness in last year) were also
found to have a statically significant association with MJAFU (p<0.0001).

4.3 Multivariate Analysis
Logistic regression was done using the PROC SURVEYLOGISTIC common ad in SAS 9.4
Both unadjusted and adjusted odds ratios were found for each dependent variable (AMDELT,
AMIYR_U and SMIYR_U). Odds ratios are detailed in Tables 4 and 5. Adjusted odds ratios
accounted for the demographic variables that was significant including age, gender, race,
income and education level. For the dependent variable any depressive episode in last year
(AMDELT), early onset marijuana use a significant predictor (AOR=2.133 95% CI 1.906-2.389
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pp<0.0001). Early onset marijuana was also a significant predictor for severe mental illness in
the past year (AOR=2.332 95% CI 1.972-2.758 p<0.0001). Early onset marijuana use also had a
moderate significance with any mental illness in last year (AOR=1.99 95% CI=1.794-2.208
p<0.0001).
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5. Discussion
5.1 Discussion of Research Questions
The purpose of this thesis was to assess the relationship between early onset marijuana
use and mental health in adult life. The research questions examined in this study were (1)
What is the prevalence of early onset marijuana use in the United States population, (2)Does
the prevalence of early onset marijuana use vary between men and women and (3) Is there an
association between early onset marijuana use (<14 years old) and adverse mental health
outcomes in adult life? This thesis found that in adults aged 18 and older the prevalence of
early onset marijuana use was 8.3%, a rate relatively similar to the reported early onset
marijuana use prevalence from the 2013 YRBSS(8.8%)53. This study also found that the
prevalence of early onset marijuana use does vary in regards to gender, with a prevalence of
5.1(95% CI 4.7-5.2) for males and 3.3(95% CI 3.1-3.5) for females. The higher prevalence of
early onset marijuana use in males is consistent with previous research findings in nationally
representative United States surveys51,53,57.
After controlling for race, age, gender, income and education level, all three outcome
measure for mental illness (serious mental illness, any mental illness and adult depressive
episode) were associated with the predicting variable early onset of marijuana use( p value <
0.0001). In individuals who reported an early onset of marijuana use, the crude odds ratio
showed a twofold increase in past year major depressive episodes compared to the non-early
onset group (COR=2.107, 95% CI =1.891-2.347, p-value <0.001). When adjusted for
demographic characteristics, the odds ratio showed a slightly higher than two fold increase in
reports of a past year depressive episode (OR=2.133, 95% CI=1.906-2.389, p-vale=<0.001).
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When early onset marijuana use was used as a predictor for past year serious mental illness
(SMIYR_U), the adjusted odds ratio found a slightly higher than two fold increase in odds
(OR=2.332, 95% CI=1.972-2.758, p-value =<.0001). This finding suggests that early onset
marijuana use has the strong association with serious mental illness in the adult life and could
be used as a predictor for mental health risk management in the adult population. The
statistical association between past year any mental illness (AMIYR_U) and early onset
marijuana use was milder than the other two dependent variables, those who reported early
onset use had an adjusted odds ratio of 1.99 compared to those who were not early onset
users(95% CI=1.794-2.208, p-value=<.0001).
While past research has shown correlations between marijuana use and acute mental
illness in adolescents or young adults, few have addressed the effects of early marijuana use on
adult mental health9,9,56,58. To our knowledge this study is the first to address early onset use of
marijuana and focus on a population who began using marijuana at the age of 14 or young in a
nationally representative sample of the U.S. population. These results hold important
implications for states considering introducing legislature legalizing the use and sale of
marijuana. The associations between early onset marijuana use and adult mental illness found
in this study could imply a trajectory for youth raised in states that allow looser access to
marijuana. Multiple studies have shown the trickledown effect of substance use from adult to
child, indicating that states where marijuana is legal may have a higher prevalence of youth
using the drug1. The impact on the population’s future health should be taken into
consideration when drafting legislature on marijuana use.
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Additionally, the prevalence of mental health disorders is growing in the United States in
both the adolescent and adult populations.26,59.Utilizatioon of mental health care is increasing,
causing a strain on the under developed behavioral health system25. The results of this study
suggest that clinicians treating mental health disorders in the adult population can assess the
potential for serious mental illness by determine the age of onset of marijuana use in their
patient population. These study findings can assist in clinician’s assessment and triage of
patients with behavior health problems and their potential for more serious mental illness in
their lifetime due to their early onset marijuana use.

5.2 Study Strengths and Limitations
This study was conducted using a cross-sectional survey of a nationally representative
sample of the U.S. population, therefore results of this study are likely generalizable to the U.S.
The large sample size, both weighted and unweighted allowed for in-depth analysis and strong
statistical power within the analysis. The data was collected using a computer assisted survey,
allowing for clarification of the questions and minimal surveyor bias in the sample. The complex
survey designed allowed for strata and weights to be applied in order to make the sample size
accurate and statistically strong. The cross-sectional design of the data and this study allows for
recall bias in the sample, especially when dealing with the independent variable which asked
the respondent to remember youth activities. The cross-sectional design also did not allow for
temporality to be established in the analysis of the associations. Additionally, the sensitive
nature of the survey questions used might have impacted the answers given by participants.
This study relied on self-reported indicators for mental illness, not diagnosis by DSM-V criteria
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which may create a bias in accuracy of mental illness in the past year or depressive episodes in
the past year.
5.3 Recommendations and Further Research
Further research should address the limitations in this study, including the lack of
temporality. A longitudinal cohort study of children that follows them into middle adulthood or
beyond would provide the temporal type of data needed. Additionally, a cohort study would
allow for better recall of exact age of first marijuana use and would eliminate much of the recall
bias present in cross-sectional survey data. Further research should also focus on the
comorbidities of early onset marijuana use such as alcohol and tobacco use in order to clarify
the impact of marijuana use. More accurate diagnostics for mental illness should be used in
future studies, such as medical records or questions such as “Have you ever been told by an MD
you have a mental illness?”. The outcomes of this study indicate that states with legal use of
marijuana should focus on strategies preventing childhood use of the drug and educating the
population on the impacts of childhood marijuana use.

5.4 Conclusion
In conclusion, these findings from a nationally representative sample of U.S. adults aged
18 and older reveal the positive associations between early onset marijuana use (aged 14 or
young) and poor mental health outcomes in adult life. Given the findings that early onset
marijuana use more than doubles the odds of reporting a past year serious mental illness,
legislations considering legalization of marijuana should take into account the exposure of
children to the drug. Strategies for the prevention of early onset marijuana use should be
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established within the U.S. to address this issue. Mental health clinicians should use assessment
tools to determine if their patient’s are at risk for serious mental illness due to their early onset
marijuana use.
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Table 1: Demographic Variables of Interest
Variable Name
Sex

Code
IRSEX

Description
Self-reported sex
at time of survey
Self-reported
education level at
time of survey

Education Level

EDUCCAT2

Age

CATAG7

Self-reported age
at time of survey

Race

NEWRACE2

Self-reported
racial/ethnic
identity

Income

INCOME

Total family
income in the past
year

Levels
1=Male
2=Female
1= Less than high
school
2= High school
graduate
3=Some college
4=College
graduate
5= 12 to 17 years
old
1= 12-13 years
2= 14-15 years
3= 16-17 years
4= 18-20 years
5= 21-25 years
6= 26-34 years
7= 30 years or
older
1= Non-Hispanic
White
2= Non-Hospice
Black/African
American
3= Non-Hispanic
Native
American/Alaskan
Native
4= Non-Hispanic
Native
Hawaiian/Other
Pacific Islander
5= Non-Hispanic
Asian
6= Non-Hispanic
more than one
race
7= Hispanic

Percent
47.62
52.38
10.18
22.68
21.65
20.88
24.61

1= Less than $20,
000
2= $20, 000-$49,
999
3= $40, 000-$74,
999
4+ $75, 000 or

21.07
31.01
16.26
31.65

7.88
8.46
8.27
8.77
14.88
15.18
35.57
60.67
12.11
1.64
0.54
4.26
3.54
17.23
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Table 2. Descriptive statistics of the analytic sample
Demographic Variable
Age
18-20
21-25
26-34
35 or older
Gender
Male
Female
Race
White
Black/African-American
Native American/Alaskan Native
Native Hawaiian/Pacific Islander
Asian
Multi-racial
Hispanic
Education Level
< High School
High School Graduate
Some College
College Graduate
Income Level (U.S. Dollars)
< 20, 000
20, 000-49, 999
50, 000-74, 999
75, 000 or greater

Frequency
n =41285

Percent

4, 782
8, 139
3, 331
20, 033

5.44
9.08
15.79
69.67

19, 210
22, 075

48.17
51.83

25, 832
4, 862
669
220
1, 818
1, 244
6, 640

65.36
11.71
0.50
0.38
5.24
1.55
15.27

5, 544
12, 389
11, 870
11, 482

13.13
28.86
27.29
30.71

9, 129
13, 098
6, 786
12, 272

18.10
30.98
16.72
34.20

Source: National Survey on Drug Use and Health, 2014
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Table 3. Chi square results of association between demographic characteristics and early onset marijuana use
Early Onset Use
Non-Early Onset Use
Demographic Characteristic
Frequency Weighted
Frequency Weighted
P-Value
Percent
Percent
Age
18-20
21-25
26-34
35 or older
Gender
Male
Female
Race
White
Black/African-American
Native American/Alaskan Native
Native Hawaiian/Pacific Islander
Asian
Multi-racial
Hispanic
Education Level
< High School
High School Graduate
Some College
College Graduate
Income Level (US Dollars)
<20, 000
20, 000-49, 999
50, 000-74, 999
75, 000 or greater

621
1033
1105
1562

0.7
1.1
2.0
4.5

4161
7106
7226
18471

4.7
8.0
13.8
66.1

<.0001

2413

5.1

16797

43.2

<.0001

1908

3.3

20167

48.5

2818
464
133
29
41
214
622

5.9
0.9
0.07
0.3
0.08
0.2
1.1

23014
4398
536
191
1777
1030
6018

59.5
10.8
0.42
0.34
5.2
1.3
14.1

<.0001

896
1493
1246
686

1.4
2.7
2.5
1.6

4648
10896
10624
10796

11.7
26.1
24.8
27.2

<.0001

1199

1.9

7930

16.2

<.0001

1455
662
1005

2.7
1.3
2.4

11643
6124
11267

28.9
15.4
31.8
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Table 4. Chi square results of association between dependent variables and early onset marijuana use

Dependent Variable

Early Onset Use
n=4321
Frequency Weighted
Percent

Non-Early Onset Use
n=36964
Frequency Weighted
Percent

PValue

Depressive Episode in Last Year(AMDELT)
Yes
No

996

1.87

4920

11.07

3325

6.45

32044

80.61

1353

2.17

6956

13.74

2968

5.84

30008

75.94

397

0.74

1594

3.45

3924

7.57

35370

88.24

<.0001

Any Mental Illness in Last Year(AMIYR_U)
Yes
No

<.0001

Severe Mental Illness In Last
Year(SMIYR_U)
Yes
No

<.0001
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Table 5. Odds Ratios of Early Onset Marijuana Use and Indicators of Adult Mental Health

OR

Early Onset Use
95% CI

Depressive Episode in Last Year(AMDELT)

2.107

1.891-2.347

Any Mental Illness in Last Year(AMIYR_U)

2.040

1.848-2.252

Severe Mental Illness In Last Year(SMIYR_U)

2.497

2.127-2.931

Mental Health Variable

P-Value
<.0001
<.0001
<.0001

Table 6. Adjusted Odds Ratios of Early Onset Marijuana Use and Indicators of Adult Mental Health

Mental Health Variable

OR

Early Onset Use
95% CI

P-Value

Depressive Episode in Last Year(AMDELT)

2.133

1.906-2.389

<0.001

Any Mental Illness in Last Year(AMIYR_U)

1.990

1.794-2.208

<.0001

Severe Mental Illness In Last Year(SMIYR_U)

2.332

1.972-2.758

<.0001
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